Get the full ebook with Bonus Features for a Better Reading Experience on ebookmeta.

com

Respiratory Symptoms Margaret L. Campbell

https://ebookmeta.com/product/respiratory-symptoms-margaret-
l-campbell/

OR CLICK HERE

DOWLOAD NOW

Download more ebook instantly today at https://ebookmeta.com

WHAT DO «
J PALLIATIVE
I DO NOW• CARE

RESPIRATORY
SYMPTOMS

EDITED BY
Margaret L , Campbell

y
i

Respiratory
Symptoms
What Do I Do Now?: Palliative Care

S E R I E S E D I TO R

Margaret L. Campbell, PhD, RN, FPCN

Professor Emeritus, Wayne University College of Nursing,
Detroit, MI

OT H E R VO L U M E S IN T HE SE RIE S

Pediatric Palliative Care, Edited by Lindsay B. Ragsdale & Elissa G. Miller

Pain, Edited by Christopher M. Herndon
iii

Respiratory
Symptoms

Edited by

Margaret L. Campbell, PhD, RN, FPCN

Professor Emeritus, Wayne University College of Nursing,
Detroit, Michigan
Oxford University Press is a department of the University of Oxford. It furthers
the University’s objective of excellence in research, scholarship, and education
by publishing worldwide. Oxford is a registered trade mark of Oxford University
Press in the UK and certain other countries.
Published in the United States of America by Oxford University Press
198 Madison Avenue, New York, NY 10016, United States of America.
© Oxford University Press 2023
All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by license, or under terms agreed with the appropriate reproduction
rights organization. Inquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above.
You must not circulate this work in any other form
and you must impose this same condition on any acquirer.
CIP data is on file at the Library of Congress
ISBN 978–​0–​19–​009889–​6
DOI: 10.1093/​med/​9780190098896.001.0001
This material is not intended to be, and should not be considered, a substitute for medical or other
professional advice. Treatment for the conditions described in this material is highly dependent on
the individual circumstances. And, while this material is designed to offer accurate information with
respect to the subject matter covered and to be current as of the time it was written, research and
knowledge about medical and health issues is constantly evolving and dose schedules for medications
are being revised continually, with new side effects recognized and accounted for regularly. Readers
must therefore always check the product information and clinical procedures with the most up-​to-​date
published product information and data sheets provided by the manufacturers and the most recent
codes of conduct and safety regulation. The publisher and the authors make no representations or
warranties to readers, express or implied, as to the accuracy or completeness of this material. Without
limiting the foregoing, the publisher and the authors make no representations or warranties as to the
accuracy or efficacy of the drug dosages mentioned in the material. The authors and the publisher do
not accept, and expressly disclaim, any responsibility for any liability, loss, or risk that may be claimed
or incurred as a consequence of the use and/​or application of any of the contents of this material.
Printed by Marquis Book Printing, Canada
v

Contents

List of Contributors vii

Introduction xi

1. Dyspnea Assessment 1
Margaret L. Campbell

2. Reducing Dyspnea by Optimizing Treatment of Chronic

Obstructive Pulmonary Disease 7
Miranda Wilhelm and Jennifer Arnoldi

3. Treating Chronic Breathlessness in Severe Chronic Obstructive

Pulmonary Disease 21
Lynn F. Reinke, Mary M. Roberts, and Tracy A. Smith

4. Dyspnea, Chronic Obstructive Pulmonary Disease, and

Pulmonary Rehabilitation 31
DorAnne Donesky and Julie Howard

5. Treating Episodic Breathlessness 39

Yvonne Eisenmann and Steffen Simon

6. Reducing Episodic Dyspnea in Heart Failure 49

Beth B. Fahlberg and Ann S. Laramee

7. Dyspnea in Pediatric Congenital Heart Disease 61

Jennifer Wright and Jessica L. Spruit

8. Treating Chronic Dyspnea in Patients with Lung Cancer 69

Elizabeth A. Higgins, Susan Ezemenari, and Julia Arana West

9. Treating Dyspnea Through Reducing Malignant Pleural

Effusion 77
Christine A. Crader

10. Treating Dyspnea in Lung Cancer with Noninvasive

Ventilation 87
Vittoria Comellini and Stefano Nava

11. Palliative Care for Infants with Bronchopulmonary

Dysplasia 95
Christine A. Fortney and Jodi A. Ulloa
vi

12. Reducing Dyspnea by Treating Ascites 101

Habib A. Khan

13. Panting for Breath in End-​Stage Dementia 109

Hermien W. Goderie-​Plomp, Carole Parsons, David R. Mehr,
and Jenny T. van der Steen

14. Last Days with Chronic Obstructive Pulmonary Disease 119

Margaret L. Campbell

15. Withdrawal of Invasive Mechanical Ventilation 125

Margaret L. Campbell

16. Palliative Sedation for Intractable Dyspnea 135

Patricia Bramati and Eduardo Bruera

17. Sialorrhea in Amyotrophic Lateral Sclerosis 145

Mark B. Bromberg

18. Death Rattle 153

Margaret L. Campbell

Index 159

vi Contents
vi

Contributors

Jennifer Arnoldi, PharmD, BCPS Christine A. Crader, MD

Clinical Associate Professor Ascension Medical Group
Southern Illinois University Internal Medicine
Edwardsville (SIUE) School of Detroit, MI, USA
Pharmacy
DorAnne Donesky, PhD,
Edwardsville, IL, USA
ANP-​BC, ACHPN, ATSF
Patricia Bramati, MD Professor, School of Nursing
The University of Texas MD Touro University of California
Anderson Cancer Center Vallejo, CA, USA
Houston, TX, USA
Yvonne Eisenmann, MD
Mark B. Bromberg, MD, PhD University of Cologne
Department of Neurology Faculty of Medicine and
University of Utah University Hospital
Salt Lake City, UT, USA Department of Palliative
Medicine
Eduardo Bruera, MD
Cologne, Germany
The University of Texas MD
Anderson Cancer Center Susan Ezemenari, MD
Houston, TX, USA Fellow, Palliative Medicine
Division of Internal Medicine,
Margaret L. Campbell, PhD,
Palliative Medicine and
RN, FPCN
Geriatrics
Wayne State University, College
Medical University of South
of Nursing
Carolina
Detroit, MI, USA
Charleston, SC, USA
Vittoria Comellini, MD
Beth B. Fahlberg, PhD, MN, RN
Respiratory and Critical Care Unit
University of Wisconsin
University Hospital St.
Madison, WI, USA
Orsola-​Malpighi
Bologna, Italy
vi

Christine A. Fortney, PhD, RN Ann S. Laramee, MS, ANP-​BC,

Assistant Professor ACNS-​BC, CHFN, ACHPN,
The Ohio State University College FHFSA
of Nursing University of Vermont
Martha S. Pitzer Center for Medical Center
Women, Children and Youth Burlington, VT, USA
Columbus, OH, USA
David R. Mehr, MD, MS
Hermien W. Goderie-​Plomp, Professor Emeritus
MD, MSc, MSc Department of Family and
Elderly Care and Palliative Care Community Medicine
Physician University of Missouri
De Zellingen, Rotterdam, The Columbia, MO, USA
Netherlands
Stefano Nava, MD
Lecturer in Palliative Care
Department of Specialistic,
Leiden University Medical Center
Diagnostic and Experimental
Leiden, The Netherlands
Medicine (DIMES), Alma
Elizabeth A. Higgins, MD Mater Studiorum University
Associate Professor of Internal of Bologna
Medicine Bologna, Italy
Division of Internal Medicine,
Carole Parsons, PhD,
Palliative Medicine and Geriatrics
MPharm, MPSNI
Medical University of South Carolina
Lecturer in Pharmacy Practice
Charleston, SC, USA
School of Pharmacy
Julie Howard, RRT, TTS, CCM Queen’s University Belfast
COPD Case Manager Belfast, UK
Adventist Health Rideout
Lynn F. Reinke, PhD, RN
Marysville, CA, USA
Claire Dumke Ryberg, RN
Habib A. Khan, MD Presidential Endowed Chair in
Johns Hopkins Medicine End-of-Life/Palliative Care
Department of Palliative Medicine University of Utah College of
Wayne State University Nursing
Baltimore, MD, USA Salt Lake City, UT, USA

viii Contributors
ix

Mary M. Roberts, MSN, RN Jodi A. Ulloa, DNP, APRN-​CNP,

Department of Respiratory NNP-​BC
and Sleep Medicine, Westmead Assistant Professor of Clinical
Hospital Practice
Ludwig Engel Centre for The Ohio State University College
Respiratory Research, Westmead of Nursing
Institute for Medical Research Martha S. Pitzer Center for
The University of Sydney at Women, Children and Youth
Westmead Hospital Columbus, OH, USA
Westmead, New South Wales,
Jenny T. van der Steen, MSc,
Australia
PhD, FGSA
Steffen Simon, MD Associate Professor
Department of Palliative Medicine Leiden University Medical Center,
University of Cologne Department of Public Health and
Faculty of Medicine and University Primary Care
Hospital Leiden, The Netherlands
Cologne, Germany Senior Researcher
Radboud University Medical
Tracy A. Smith, MD
Center, Department of Primary
Department of Respiratory and
and Community Care
Sleep Medicine, Westmead Hospital
Nijmegen, The Netherlands
The University of Sydney at
Westmead Hospital Julia Arana West, MD
Westmead, New South Wales, Fellow, Palliative Medicine
Australia Division of Internal Medicine,
Palliative Medicine and Geriatrics
Jessica L. Spruit, DNP, CPNP-​AC
Attending Physician, Department
Pediatric Nurse Practitioner
of Emergency Medicine
Stepping Stones Pediatric Palliative
Medical University of South
Care Program
Carolina
University of Michigan
Charleston, SC, USA
Health System
Ann Arbor, MI, USA

Contributors ix
x

Miranda Wilhelm, PharmD Jennifer Wright, MS, CPNP

Clinical Associate Professor Stepping Stones Pediatric
Southern Illinois University Palliative Care
Edwardsville (SIUE) School of Michigan Medicine
Pharmacy Ann Arbor, MI, USA
Edwardsville, IL, USA

x Contributors
xi

Introduction

Margaret L. Campbell

In this volume, nearly all the chapters relate to the complex symptom
dyspnea across diagnoses, lifespan, and care settings. Other chapters relate
to oral and pharyngeal secretions. These topics are addressed from a pallia-
tive care context.
Dyspnea, also known as breathlessness, has been defined as a person’s
awareness of uncomfortable or distressing breathing. As this can only
be known by the person, the term “respiratory distress” is used as the
observed corollary relying on patient signs when the person is unable to
report dyspnea, such as infants, young children, and adults with cognitive
impairments, which may be acute or chronic.
Dyspnea develops when inspiratory effort, hypoxemia, and/​ or
hypercarbia develops, which activates three redundant brain areas. In the
cerebral cortex, the dyspneic person has an awareness of the change in
breathing efficiency. The amygdala in the subcortical temporal lobe is ac-
tivated when there is a threat to survival and produces a fear response. The
pons in the brainstem reacts by activating compensatory accelerations of
heart and respiratory rates and recruiting accessory muscles.
Assessment of dyspnea relies on self-​report from as simple as a yes-​
or-​no response to the query “Are you short of breath?” to more complex
numeric scales (0–​10) or categorical scales (none, mild, moderate, or se-
vere). For patients unable to report dyspnea, observation scales such as the
Respiratory Distress Observation Scale may be used. High-​risk patients
should be assessed at every clinical encounter.
Dyspnea is one of the most difficult symptoms to experience and is also
one of the most difficult to treat, as the evidence base for this symptom
lags behind other prevalent symptoms such as pain or nausea, to name
two. Dyspnea is prevalent in patients with cardiopulmonary disorders and
cancer, and it escalates as death approaches. The development of dyspnea in
chronic disease is a predictor of mortality.
Dyspnea may be acute when a reversible etiology presents such as pneu-
monia, pleural effusion, or ascites. It is chronic in an irreversible condition
xi

such as chronic obstructive pulmonary disease (COPD), advanced heart

failure, or congenital cardiac conditions. Episodic dyspnea may typify acute
exacerbations in chronic conditions such as heart failure.
Treating dyspnea relies on a hierarchy of responses, beginning with
treating underlying, reversible conditions such as infections, pleural
effusions, volume overload, or ascites. Nonpharmacological treatments
include pulmonary rehabilitation, noninvasive ventilation, balancing rest
with activity, and optimal positioning. Pharmacological treatments include
oxygen, bronchodilators, and opioids. In cases of refractory dyspnea, palli-
ative sedation may be indicated.
Patients receiving invasive mechanical ventilation for respiratory failure
may undergo ventilator withdrawal to afford a natural death. These patients
are at very high risk for developing respiratory distress, which warrants
careful attention to the processes to minimize distress.
Salivary secretions pose a significant problem for patients with bulbar-​
onset amyotrophic lateral sclerosis characterized by difficulties swallowing.
Treatment begins with anticholinergic medications and may include botu-
linum toxin injections or irradiation of salivary glands.
Pharyngeal secretions, also known as death rattle, develops in about
half of dying patients in the last days of life. Controversies about whether
medications are indicated or effective make up the evidence base. Ethical
concerns about medicating the patient to assuage the listener have been
raised.
The contributors to this volume have addressed all the treatments cur-
rently known for dyspnea, respiratory distress, and secretions with a case
study approach.

xii Introduction
1 Dyspnea Assessment

Margaret L. Campbell

Stella is a nursing home resident in the advanced

stage of Alzheimer’s disease. Her goals of care are
comfort-​focused, with surrogate decisions previously
made to withhold tube feedings, intubation,
cardiopulmonary resuscitation, and hospitalization.
She sleeps most of the day and night and is
noncommunicative except for sounds of displeasure
such as when being bathed or turned. Stella is at high
risk for aspiration pneumonia; she is offered a soft,
easy-​to-​swallow diet with foods such as pudding,
scrambled eggs, oatmeal, and baby food.
On daily exam a change in her breathing is noted; it
is highly likely that Stella has developed pneumonia,
probably secondary to immobility or food or liquid
aspiration. The clinical team cannot elicit a dyspnea
assessment from Stella, and they know she is at risk
for respiratory distress.

What do I do now?

1
2

WHAT IS DYSPNEA?

Dyspnea is a person’s awareness of uncomfortable or distressing breathing

that can only be known by self-​report. In symptom care a patient’s self-​
report has long been held as the gold standard for assessment. In a palli-
ative care context dyspnea should be assessed at every patient encounter,
for example in the hospital whenever vital signs are obtained, or at every
outpatient clinic visit, or at every house call for home-​bound patients.
Since dyspnea escalates as death nears, the frequency of assessment should
be increased. Several tools are available for measuring and trending dyspnea
that are appropriate in palliative care.

Unidimensional Assessment Tools

Responding to a symptom assessment requires several cognitive steps on
the patient’s part: (1) ascertain their sensation, (2) pay attention to the
clinician’s assessment instructions, (3) formulate a response, (4) commu-
nicate that response in some fashion, and (5) recall their previous report if
trending is requested. When a patient is feeling poorly or is fatigued, these
steps may pose difficulty and simpler tools are indicated.
The simplest measure is to ask for a “yes” or “no” response to the query
“Are you short of breath?” or, in the case of the mechanically ventilated
patient, “Are you getting enough air?” Knowing the presence or absence of
dyspnea is helpful, but its intensity cannot be assessed with this approach.
A more complex tool is a numeric rating scale, usually anchored at 0 for no
dyspnea and 10 for the worst possible dyspnea. Patients may need guidance
on how to use numbers to characterize their symptom intensity. A variation
to using numbers is to ask for a categorical ranking (none, mild, moderate,
severe). Some patients may find these categorical rankings easier to under-
stand and relate to their experience than a numeric rating.
Another variation that can be used to rate intensity is a visual analog
scale, typically a 100-​mm scale anchored at 0 and 100, with tick marks
at every 10 points (Figure 1.1). The patient points to a line on the scale
representing their experience and the clinician can convert that to a nu-
meric score; this approach is useful in the critical care setting with patients
who are mechanically ventilated and nonverbal. A vertical scale was pre-
ferred by patients with chronic obstructive pulmonary disease (COPD).1

2 WHAT DO I DO NOW? Respiratory Symptoms

Random documents with unrelated
content Scribd suggests to you:
And I should never have guessed Sir Keith to be the kind of
man either.

However, of course tastes differ, and they ought to know

their own minds. I am glad it is not Nellie.

July 29. Thursday.—Just ten days since I sent my last

MS. to Mr. Willis.

After so many months of disappointment, one thing

after another failing, I could hardly be hopeful. I could only
pray and wait,—feeling that most likely I was not to have a
book out at all this year. But I have worked hard with this
tale, and I did do my very best.

Now the answer has come. Mr. Willis offers me thirty

pounds for the first edition of 2000 copies: the copyright
after that remaining in my hands. He says the story seems
"interesting and well written," and he "hopes it may have a
fairly good circulation."

At all events, the heroine is not too disagreeable this

time!

I have written to accept the offer: and I do feel very

happy about it.

It has been desperately hot weather lately: and I

wanted so much to get it done, that I have been copying at
the rate of forty to seventy MS. pages a day. But it was
worth while. And I am only just in time for the autumn.

But I can see the good of failures,—even coming one

after another. A year ago I was getting too confident, and
perhaps careless. I think I have learnt a lesson for life.

August 15. Wednesday.—Plans seem settling into shape.

About the middle of September the Romillys all come south;
and early in October the double wedding will, it is hoped,
take place. How droll to think of Thyrza as "Lady Denham!"

Miss Con is to be married from Glynde House; and

perhaps her sister may be present. Not Mr. Smyth, for he
never goes anywhere. He is too fat.

And I am to be one of Miss Con's bridesmaids!

Miss Con writes so brightly. She seems full of happiness.

Her knee is almost well again, which is a great comfort.

She has been very busy lately, finding a situation for

Miss Millington, as companion to an old lady in Bath, and
also making arrangements about a home for the younger
sister.

So like Miss Con!

THE END.

Printed by BALLANTYNE, HANSON & CO.

 Edinburgh & London

James Nisbet & Co.'s List.

By AGNES GIBERNE.

"Tales that bear Miss Giberne's name are 'the

best of the best.' No writer excels her in this
department of literature."—Fireside News.

"That the story is Miss Giberne's guarantees

refinement and Christian principle."—
Churchman.

_______________________

THE DALRYMPLES. With Illustrations. Cheap Edition. 1s. 6d.

"An interesting tale, exhibiting some striking situations."—
Church Bells.

"LEAST SAID, SOONEST MENDED." Cheap Edition. 1s. 6d.

"To say that it is by Miss Giberne is at once to recommend
the story highly to girls."—Quiver.

NUMBER THREE WINIFRED PLACE. Cheap Edition. 1s. 6d.

"A delightful story, and, we need hardly add—being Miss
Giberne's—is full of the highest and most profitable religious
teaching."—Record.

"Miss Giberne's book is for gentler readers. It appeals very

delicately to their softer sympathies, and introduces them to
one young girl
at least who may serve as a model or ideal to them. It is
written in a pleasing sympathetic style."—Scotsman.

MISS CON; or, All Those Girls. 2s. 6d.

"Constance Conway is a charming heroine. Her diary is an
admirable collection of character sketches."—Athenæum.

ENID'S SILVER BOND. 2s. 6d.

"Enid's nature is essentially heroic . . . The other
characters are cleverly sketched."—Times.

ST. AUSTIN'S LODGE; or, Mr. Berkeley and his Nieces. 2s. 6d.
"A very good example of the author's well-known style. It is
carefully written, and is in all respects a conscientious
performance."—Academy.

Prize and Gift Books.

AGNES GIBERNE'S WORKS—continued.

BERYL AND PEARL. Illustrated. 2s. 6d.

"One of Miss Giberne's most delightful tales."—Record.

KATHLEEN. Illustrated. Crown 8vo. 2s. 6d.

"A fascinating tale."—Record.
SWEETBRIAR. Illustrated. 1s. 6d.

AIMÉE: A Tale of the Days of James the Second. Illustrated.

Crown 8vo. 2s. 6d.

DECIMA'S PROMISE. 2s. 6d.

"One of the best and soundest books we have seen."—Public
Opinion.

READY, AYE READY! 1s. 6d.

"A charming story, which displays all this well-known
writer's knowledge of girls and their habits of mind."—
Scotsman.

DAISY OF OLD MEADOW. 1s.

"There are few boys or girls to whom this story will not
prove interesting reading."—Court Circular.

OLD UMBRELLAS; or, Clarrie and her Mother. 1s.

"This book is bright and lively, and will be read with
pleasure and profit."—Christian.

MILES MURCHISON. Illustrated. Small crown 8vo. 1s.

 *** END OF THE PROJECT GUTENBERG EBOOK MISS CON ***

Updated editions will replace the previous one—the old editions will
be renamed.

Creating the works from print editions not protected by U.S.

copyright law means that no one owns a United States copyright in
these works, so the Foundation (and you!) can copy and distribute it
in the United States without permission and without paying
copyright royalties. Special rules, set forth in the General Terms of
Use part of this license, apply to copying and distributing Project
Gutenberg™ electronic works to protect the PROJECT GUTENBERG™
concept and trademark. Project Gutenberg is a registered trademark,
and may not be used if you charge for an eBook, except by following
the terms of the trademark license, including paying royalties for use
of the Project Gutenberg trademark. If you do not charge anything
for copies of this eBook, complying with the trademark license is
very easy. You may use this eBook for nearly any purpose such as
creation of derivative works, reports, performances and research.
Project Gutenberg eBooks may be modified and printed and given
away—you may do practically ANYTHING in the United States with
eBooks not protected by U.S. copyright law. Redistribution is subject
to the trademark license, especially commercial redistribution.

START: FULL LICENSE

THE FULL PROJECT GUTENBERG LICENSE
 PLEASE READ THIS BEFORE YOU DISTRIBUTE OR USE THIS WORK

To protect the Project Gutenberg™ mission of promoting the free

distribution of electronic works, by using or distributing this work (or
any other work associated in any way with the phrase “Project
Gutenberg”), you agree to comply with all the terms of the Full
Project Gutenberg™ License available with this file or online at
www.gutenberg.org/license.

Section 1. General Terms of Use and

Redistributing Project Gutenberg™
electronic works
1.A. By reading or using any part of this Project Gutenberg™
electronic work, you indicate that you have read, understand, agree
to and accept all the terms of this license and intellectual property
(trademark/copyright) agreement. If you do not agree to abide by all
the terms of this agreement, you must cease using and return or
destroy all copies of Project Gutenberg™ electronic works in your
possession. If you paid a fee for obtaining a copy of or access to a
Project Gutenberg™ electronic work and you do not agree to be
bound by the terms of this agreement, you may obtain a refund
from the person or entity to whom you paid the fee as set forth in
paragraph 1.E.8.

1.B. “Project Gutenberg” is a registered trademark. It may only be

used on or associated in any way with an electronic work by people
who agree to be bound by the terms of this agreement. There are a
few things that you can do with most Project Gutenberg™ electronic
works even without complying with the full terms of this agreement.
See paragraph 1.C below. There are a lot of things you can do with
Project Gutenberg™ electronic works if you follow the terms of this
agreement and help preserve free future access to Project
Gutenberg™ electronic works. See paragraph 1.E below.
1.C. The Project Gutenberg Literary Archive Foundation (“the
Foundation” or PGLAF), owns a compilation copyright in the
collection of Project Gutenberg™ electronic works. Nearly all the
individual works in the collection are in the public domain in the
United States. If an individual work is unprotected by copyright law
in the United States and you are located in the United States, we do
not claim a right to prevent you from copying, distributing,
performing, displaying or creating derivative works based on the
work as long as all references to Project Gutenberg are removed. Of
course, we hope that you will support the Project Gutenberg™
mission of promoting free access to electronic works by freely
sharing Project Gutenberg™ works in compliance with the terms of
this agreement for keeping the Project Gutenberg™ name associated
with the work. You can easily comply with the terms of this
agreement by keeping this work in the same format with its attached
full Project Gutenberg™ License when you share it without charge
with others.

1.D. The copyright laws of the place where you are located also
govern what you can do with this work. Copyright laws in most
countries are in a constant state of change. If you are outside the
United States, check the laws of your country in addition to the
terms of this agreement before downloading, copying, displaying,
performing, distributing or creating derivative works based on this
work or any other Project Gutenberg™ work. The Foundation makes
no representations concerning the copyright status of any work in
any country other than the United States.

1.E. Unless you have removed all references to Project Gutenberg:

1.E.1. The following sentence, with active links to, or other

immediate access to, the full Project Gutenberg™ License must
appear prominently whenever any copy of a Project Gutenberg™
work (any work on which the phrase “Project Gutenberg” appears,
or with which the phrase “Project Gutenberg” is associated) is
accessed, displayed, performed, viewed, copied or distributed:
 This eBook is for the use of anyone anywhere in the United
States and most other parts of the world at no cost and with
almost no restrictions whatsoever. You may copy it, give it away
or re-use it under the terms of the Project Gutenberg License
included with this eBook or online at www.gutenberg.org. If you
are not located in the United States, you will have to check the
laws of the country where you are located before using this
eBook.

1.E.2. If an individual Project Gutenberg™ electronic work is derived

from texts not protected by U.S. copyright law (does not contain a
notice indicating that it is posted with permission of the copyright
holder), the work can be copied and distributed to anyone in the
United States without paying any fees or charges. If you are
redistributing or providing access to a work with the phrase “Project
Gutenberg” associated with or appearing on the work, you must
comply either with the requirements of paragraphs 1.E.1 through
1.E.7 or obtain permission for the use of the work and the Project
Gutenberg™ trademark as set forth in paragraphs 1.E.8 or 1.E.9.

1.E.3. If an individual Project Gutenberg™ electronic work is posted

with the permission of the copyright holder, your use and distribution
must comply with both paragraphs 1.E.1 through 1.E.7 and any
additional terms imposed by the copyright holder. Additional terms
will be linked to the Project Gutenberg™ License for all works posted
with the permission of the copyright holder found at the beginning
of this work.

1.E.4. Do not unlink or detach or remove the full Project

Gutenberg™ License terms from this work, or any files containing a
part of this work or any other work associated with Project
Gutenberg™.

1.E.5. Do not copy, display, perform, distribute or redistribute this

electronic work, or any part of this electronic work, without
prominently displaying the sentence set forth in paragraph 1.E.1
with active links or immediate access to the full terms of the Project
Gutenberg™ License.

1.E.6. You may convert to and distribute this work in any binary,
compressed, marked up, nonproprietary or proprietary form,
including any word processing or hypertext form. However, if you
provide access to or distribute copies of a Project Gutenberg™ work
in a format other than “Plain Vanilla ASCII” or other format used in
the official version posted on the official Project Gutenberg™ website
(www.gutenberg.org), you must, at no additional cost, fee or
expense to the user, provide a copy, a means of exporting a copy, or
a means of obtaining a copy upon request, of the work in its original
“Plain Vanilla ASCII” or other form. Any alternate format must
include the full Project Gutenberg™ License as specified in
paragraph 1.E.1.

1.E.7. Do not charge a fee for access to, viewing, displaying,

performing, copying or distributing any Project Gutenberg™ works
unless you comply with paragraph 1.E.8 or 1.E.9.

1.E.8. You may charge a reasonable fee for copies of or providing

access to or distributing Project Gutenberg™ electronic works
provided that:

• You pay a royalty fee of 20% of the gross profits you derive
from the use of Project Gutenberg™ works calculated using the
method you already use to calculate your applicable taxes. The
fee is owed to the owner of the Project Gutenberg™ trademark,
but he has agreed to donate royalties under this paragraph to
the Project Gutenberg Literary Archive Foundation. Royalty
payments must be paid within 60 days following each date on
which you prepare (or are legally required to prepare) your
periodic tax returns. Royalty payments should be clearly marked
as such and sent to the Project Gutenberg Literary Archive
Foundation at the address specified in Section 4, “Information
 about donations to the Project Gutenberg Literary Archive
Foundation.”

• You provide a full refund of any money paid by a user who

notifies you in writing (or by e-mail) within 30 days of receipt
that s/he does not agree to the terms of the full Project
Gutenberg™ License. You must require such a user to return or
destroy all copies of the works possessed in a physical medium
and discontinue all use of and all access to other copies of
Project Gutenberg™ works.

• You provide, in accordance with paragraph 1.F.3, a full refund of

any money paid for a work or a replacement copy, if a defect in
the electronic work is discovered and reported to you within 90
days of receipt of the work.

• You comply with all other terms of this agreement for free
distribution of Project Gutenberg™ works.

1.E.9. If you wish to charge a fee or distribute a Project Gutenberg™

electronic work or group of works on different terms than are set
forth in this agreement, you must obtain permission in writing from
the Project Gutenberg Literary Archive Foundation, the manager of
the Project Gutenberg™ trademark. Contact the Foundation as set
forth in Section 3 below.

1.F.

1.F.1. Project Gutenberg volunteers and employees expend

considerable effort to identify, do copyright research on, transcribe
and proofread works not protected by U.S. copyright law in creating
the Project Gutenberg™ collection. Despite these efforts, Project
Gutenberg™ electronic works, and the medium on which they may
be stored, may contain “Defects,” such as, but not limited to,
incomplete, inaccurate or corrupt data, transcription errors, a
copyright or other intellectual property infringement, a defective or
damaged disk or other medium, a computer virus, or computer
codes that damage or cannot be read by your equipment.

1.F.2. LIMITED WARRANTY, DISCLAIMER OF DAMAGES - Except for

the “Right of Replacement or Refund” described in paragraph 1.F.3,
the Project Gutenberg Literary Archive Foundation, the owner of the
Project Gutenberg™ trademark, and any other party distributing a
Project Gutenberg™ electronic work under this agreement, disclaim
all liability to you for damages, costs and expenses, including legal
fees. YOU AGREE THAT YOU HAVE NO REMEDIES FOR
NEGLIGENCE, STRICT LIABILITY, BREACH OF WARRANTY OR
BREACH OF CONTRACT EXCEPT THOSE PROVIDED IN PARAGRAPH
1.F.3. YOU AGREE THAT THE FOUNDATION, THE TRADEMARK
OWNER, AND ANY DISTRIBUTOR UNDER THIS AGREEMENT WILL
NOT BE LIABLE TO YOU FOR ACTUAL, DIRECT, INDIRECT,
CONSEQUENTIAL, PUNITIVE OR INCIDENTAL DAMAGES EVEN IF
YOU GIVE NOTICE OF THE POSSIBILITY OF SUCH DAMAGE.

1.F.3. LIMITED RIGHT OF REPLACEMENT OR REFUND - If you

discover a defect in this electronic work within 90 days of receiving
it, you can receive a refund of the money (if any) you paid for it by
sending a written explanation to the person you received the work
from. If you received the work on a physical medium, you must
return the medium with your written explanation. The person or
entity that provided you with the defective work may elect to provide
a replacement copy in lieu of a refund. If you received the work
electronically, the person or entity providing it to you may choose to
give you a second opportunity to receive the work electronically in
lieu of a refund. If the second copy is also defective, you may
demand a refund in writing without further opportunities to fix the
problem.

1.F.4. Except for the limited right of replacement or refund set forth
in paragraph 1.F.3, this work is provided to you ‘AS-IS’, WITH NO
OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR ANY PURPOSE.

1.F.5. Some states do not allow disclaimers of certain implied

warranties or the exclusion or limitation of certain types of damages.
If any disclaimer or limitation set forth in this agreement violates the
law of the state applicable to this agreement, the agreement shall be
interpreted to make the maximum disclaimer or limitation permitted
by the applicable state law. The invalidity or unenforceability of any
provision of this agreement shall not void the remaining provisions.

1.F.6. INDEMNITY - You agree to indemnify and hold the Foundation,

the trademark owner, any agent or employee of the Foundation,
anyone providing copies of Project Gutenberg™ electronic works in
accordance with this agreement, and any volunteers associated with
the production, promotion and distribution of Project Gutenberg™
electronic works, harmless from all liability, costs and expenses,
including legal fees, that arise directly or indirectly from any of the
following which you do or cause to occur: (a) distribution of this or
any Project Gutenberg™ work, (b) alteration, modification, or
additions or deletions to any Project Gutenberg™ work, and (c) any
Defect you cause.

Section 2. Information about the Mission

of Project Gutenberg™
Project Gutenberg™ is synonymous with the free distribution of
electronic works in formats readable by the widest variety of
computers including obsolete, old, middle-aged and new computers.
It exists because of the efforts of hundreds of volunteers and
donations from people in all walks of life.

Volunteers and financial support to provide volunteers with the

assistance they need are critical to reaching Project Gutenberg™’s
goals and ensuring that the Project Gutenberg™ collection will
remain freely available for generations to come. In 2001, the Project
Gutenberg Literary Archive Foundation was created to provide a
secure and permanent future for Project Gutenberg™ and future
generations. To learn more about the Project Gutenberg Literary
Archive Foundation and how your efforts and donations can help,
see Sections 3 and 4 and the Foundation information page at
www.gutenberg.org.

Section 3. Information about the Project

Gutenberg Literary Archive Foundation
The Project Gutenberg Literary Archive Foundation is a non-profit
501(c)(3) educational corporation organized under the laws of the
state of Mississippi and granted tax exempt status by the Internal
Revenue Service. The Foundation’s EIN or federal tax identification
number is 64-6221541. Contributions to the Project Gutenberg
Literary Archive Foundation are tax deductible to the full extent
permitted by U.S. federal laws and your state’s laws.

The Foundation’s business office is located at 809 North 1500 West,

Salt Lake City, UT 84116, (801) 596-1887. Email contact links and up
to date contact information can be found at the Foundation’s website
and official page at www.gutenberg.org/contact

Section 4. Information about Donations to

the Project Gutenberg Literary Archive
Foundation
Project Gutenberg™ depends upon and cannot survive without
widespread public support and donations to carry out its mission of
increasing the number of public domain and licensed works that can
be freely distributed in machine-readable form accessible by the
widest array of equipment including outdated equipment. Many
small donations ($1 to $5,000) are particularly important to
maintaining tax exempt status with the IRS.

The Foundation is committed to complying with the laws regulating

charities and charitable donations in all 50 states of the United
States. Compliance requirements are not uniform and it takes a
considerable effort, much paperwork and many fees to meet and
keep up with these requirements. We do not solicit donations in
locations where we have not received written confirmation of
compliance. To SEND DONATIONS or determine the status of
compliance for any particular state visit www.gutenberg.org/donate.

While we cannot and do not solicit contributions from states where

we have not met the solicitation requirements, we know of no
prohibition against accepting unsolicited donations from donors in
such states who approach us with offers to donate.

International donations are gratefully accepted, but we cannot make

any statements concerning tax treatment of donations received from
outside the United States. U.S. laws alone swamp our small staff.

Please check the Project Gutenberg web pages for current donation
methods and addresses. Donations are accepted in a number of
other ways including checks, online payments and credit card
donations. To donate, please visit: www.gutenberg.org/donate.

Section 5. General Information About

Project Gutenberg™ electronic works
Professor Michael S. Hart was the originator of the Project
Gutenberg™ concept of a library of electronic works that could be
freely shared with anyone. For forty years, he produced and
distributed Project Gutenberg™ eBooks with only a loose network of
volunteer support.
Project Gutenberg™ eBooks are often created from several printed
editions, all of which are confirmed as not protected by copyright in
the U.S. unless a copyright notice is included. Thus, we do not
necessarily keep eBooks in compliance with any particular paper
edition.

Most people start at our website which has the main PG search
facility: www.gutenberg.org.

This website includes information about Project Gutenberg™,

including how to make donations to the Project Gutenberg Literary
Archive Foundation, how to help produce our new eBooks, and how
to subscribe to our email newsletter to hear about new eBooks.